Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor.

about

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor.

Item

http://www.wikidata.org/entity/Q38776931

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor.

@en

type

Item

label

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor.

@en

prefLabel

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor.

@en

P1476

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor.

@en

P2093

Antoine Italiano

http://www.w3.org/2001/XMLSchema#string

Jean-Michel Coindre

http://www.w3.org/2001/XMLSchema#string

Michèle Kind

http://www.w3.org/2001/XMLSchema#string

Thomas Grellety

http://www.w3.org/2001/XMLSchema#string

P2860

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region.

The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000.

Gastrointestinal stromal tumours: origin and molecular oncology.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial

KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.

P304

FSO33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.4155/FSO.15.33

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28031906

http://www.w3.org/2001/XMLSchema#string

P932

5137998

http://www.w3.org/2001/XMLSchema#string